Nitin TELANG

Palindrome Liaisons Consultants, USA

Title: Natural products as therapeutic alternatives for triple-negative breast cancer

Abstract

Rationale: The triple-negative breast cancer (TNBC) represents the most aggressive breast cancer subtype. Because of a lack of expression of estrogen receptor-? (ER-?), progesterone receptor (PR) and amplified human epidermal growth factor-2 (HER-2) conventional multi-drug cytotoxic chemotherapy represents the only treatment option for TNBC. Long-term conventional chemotherapy is associated with systemic toxicity, spontaneous or acquired tumor resistance and emergence of therapy resistant stem cells that together facilitate cancer progression. These limitations emphasize an unmet need for identification of nontoxic natural products as testable therapeutic alternatives for TNBC. Several naturally-occurring agents such as dietary phytochemicals are widely consumed by human population and lack detectable systemic toxicity. Formulations prepared from Chinese nutritional herbs are widely used in traditional Chinese medicine as palliative treatment for breast cancer patients. Thus, natural products such as dietary phytochemicals and nutritional herbs may function as testable alternatives. Published Evidence: Preclinical efficacy of dietary phytochemicals and Chinese medicinal products has been documented in several breast carcinoma derived cellular models, as well as in models for cancer stem cells. Anti-proliferative and pro-apoptotic effects of mechanistically distinct Chinese nutritional herbs have been documented in a human breast carcinoma-derived cellular model for TNBC. At the mechanistic levels these herbs are known to affect the cell survival pathways that are activated in cancer cells. Presentation Summary: This presentation will provide an overview of published evidence relevant to the growth inhibitory effects of select Chinese nutritional herbs on a cellular model for TNBC, mechanistic leads and identification of potential molecular targets for their efficacy. Collectively, the discussed evidence will support the hypothesis that natural products may provide testable therapeutic alternatives for therapy-resistant TNBC.

Biography

Nitin TELANG is the Director, Cancer Prevention Research Program at Palindrome Liaisons Consultants, New Jersey. He earned his Ph.D. degree in India (1974), and obtained the post-doctoral training at University of Nebraska, American Health Foundation, New York and Memorial Sloan-Kettering Cancer Center, New York (1976-1985). He has served as a faculty member at Memorial Sloan-Kettering Cancer Center, Weill-Cornell Medical College, and Strang Cancer Prevention Center, New York (1986-2007). Dr. TELANG has published more than 150 peer-reviewed papers in the areas of carcinogenesis, cancer prevention, and cancer stem cell biology. He has served on Grant Review Study Sections for National Cancer Institute (NCI) and US Department of Defense Breast Cancer Research Program (DOD-BCRP). He is on the editorial boards for Oncology Reports, International Journal of Oncology, World Academy of Sciences Journal and International Journal of Molecular Sciences- Molecular Pharmacology. His research has been funded by grants from NCI and DOD. He has received NCI FIRST Award, DOD-BCRP IDEA Award and AN Marquis Lifetime Achievement Award.

4th International Conference on Oncology Research and Treatment

Nitin TELANG

Title: Natural products as therapeutic alternatives for triple-negative breast cancer

Abstract

Biography

Organization Location

Mail us at

Our Social Presence

Call us at